GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB) Marinkovich, M., Gonzalez, M., Guide, S., Bagci, I. S., Chitra, S., Agostini, B., Chen, H., Parry, T., Krishnan, S. ELSEVIER SCIENCE INC. 2022: S79

View details for Web of Science ID 000829693001020